Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA(®) trial

OBJECTIVE: Linagliptin, a dipeptidyl peptidase-4 inhibitor, demonstrated cardiovascular and renal safety in type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) with albuminuria and/or kidney disease in the multinational CARMELINA(®) trial. We investigated the effec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetol Int
Asıl Yazarlar: Inagaki, Nobuya, Yang, Wenying, Watada, Hirotaka, Ji, Linong, Schnaidt, Sven, Pfarr, Egon, Okamura, Tomoo, Johansen, Odd Erik, George, Jyothis T., von Eynatten, Maximilian, Rosenstock, Julio, Perkovic, Vlado, Wanner, Christoph, Cooper, Mark E., Alexander, John H., Komuro, Issei, Nangaku, Masaomi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Singapore 2019
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7082467/
https://ncbi.nlm.nih.gov/pubmed/32206483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13340-019-00412-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller